5 Pharmaceutical Stocks to Buy Now

by Portfolio Grader | November 1, 2013 3:15 pm

The grades of five Pharmaceutical stocks are on the rise this week on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, TherapeuticsMD, Inc. (AMEX:TXMD[2]) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). TherapeuticsMD operates as a women’s healthcare product company in the United States. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, TXMD also gets A’s. For more information, get Portfolio Grader’s complete analysis of TXMD stock[3].

Johnson & Johnson (NYSE:JNJ[4]) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. Shares of JNJ have increased 6.3% over the past month, better than the 1.7% decrease the S&P 500 has seen over the same period of time. The stock has a dividend yield of 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock[5].

Bristol-Myers Squibb Company (NYSE:BMY[6]) boosts its rating from a C to a B this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. Wall Street has pushed the stock higher by 11.8% over the past month. For more information, get Portfolio Grader’s complete analysis of BMY stock[7].

Watson Pharmaceuticals (NYSE:WPI[8]) earns an A this week, jumping up from last week’s grade of B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock[9].

This is a strong week for Repros Therapeutics (NASDAQ:RPRX[10]). The company’s rating climbs to A from the previous week’s B. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock[11].

Louis Navellier’s proprietary Portfolio Grader[12] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[13].

Source URL: https://investorplace.com/2013/11/5-pharmaceutical-stocks-to-buy-now-txmd-jnj-bmy-3/

---